What You Should Know:
– Doximity, a digital platform for U.S. medical professionals, has acquired Pathway Medical Inc., a Montreal-based startup specializing in medical AI and evidence-based clinical reference.
– The acquisition, valued at $26M in cash with up to an additional $37M in equity grants, closed on July 29, 2025. The strategic move is set to significantly enhance Doximity’s clinical reference capabilities by integrating Pathway’s advanced AI platform and extensive medical dataset.
A Data-Driven Approach to Clinical Accuracy
Pathway’s team, which is half-comprised of physicians, has spent seven years meticulously building one of the largest structured datasets in medicine. This dataset, purpose-built for AI, covers nearly every medical guideline, drug, and landmark trial across all major specialties. This rigorous, evidence-based foundation is a key reason for Pathway’s success; its AI model recently achieved a record-breaking 96% on the U.S. Medical Licensing Examination (USMLE) benchmark, outperforming other models in clinical accuracy.
The merger of Pathway and Doximity is poised to democratize access to these cutting-edge clinical tools. Pathway has already garnered a strong following, with hundreds of thousands of registered users and thousands paying for its premium product. By integrating its technology into Doximity’s platform, Pathway’s CEO, Jon Hershon, is excited to “bring that experience to millions for free, built directly into the tools they already use at the point of care.”
Bringing AI-Powered Tools to Millions of Doctors
The acquisition will address the growing need for clinical tools that combine trusted, evidence-based information with the speed and adaptability of AI. With Doximity’s vast network, which includes over 80% of U.S. physicians, the integration of Pathway’s AI will empower an enormous user base with instant, evidence-based answers to medical questions, helping doctors be more productive and provide better care for their patients.
Jeff Tangney, co-founder and CEO of Doximity, expressed his enthusiasm for the acquisition, stating, “They’ve painstakingly built one of the best datasets in medicine, and it’s going to take our clinical reference capabilities to an entirely new level.”
